NCT00840047Active, not recruitingPhase 2
Methionine PET/CT Studies In Patients With Cancer
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to test the usefulness of imaging with radiolabeled methionine in the evaluation of children and young adults with tumor(s). Methionine is a naturally occurring essential amino acid. It is crucial for the formation of proteins. When labeled with carbon-11 (C-11), a radioactive isotope of the naturally occurring carbon-12, the distribution of methionine can be determined noninvasively using a PET (positron emission tomography) camera. C-11 methionine (MET) has been shown valuable in the monitoring of a large number of neoplasms. Since C-11 has a short half life (20 minutes), MET must be produced in a facility very close to its intended use. Thus, it is not widely available and is produced only at select institutions with access to a cyclotron and PET chemistry facility. With the new availability of short lived tracers produced by its PET chemistry unit, St. Jude Children's Research Hospital (St. Jude) is one of only a few facilities with the capabilities and interests to evaluate the utility of PET scanning in the detection of tumors, evaluation of response to therapy, and distinction of residual tumor from scar tissue in patients who have completed therapy. The investigators propose to examine the biodistribution of MET in patients with malignant solid neoplasms, with emphasis on central nervous system (CNS) tumors and sarcomas. This project introduces a new diagnostic test for the noninvasive evaluation of neoplasms in pediatric oncology. Although not the primary purpose of this proposal, the investigators anticipate that MET studies will provide useful clinical information for the management of patients with malignant neoplasms.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 503 (actual)
- First submitted
- 9 Feb 2009
- Start date
- 20 Jul 2009
- Primary completion date
- 27 Jul 2027
- Lead sponsor
- St. Jude Children's Research Hospital
- Diseases
- Hodgkin lymphoma, Neuroblastoma, Childhood cancers, Sarcoma
- NCT number
- NCT00840047
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 503
- From 20 Jul 2009 to the primary completion date, 27 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- More than 6 MET PET scans within the previous 12 months.
- More than 6 MET PET scans within the previous 12 months.
Other
- Inability or unwillingness of research participant, parent, or legal guardian/representative to give written informed consent.
- Inability or unwillingness of research participant, parent, or legal guardian/representative to give written informed consent.
Who the study is looking for
- All participants under the care of St. Jude physicians with known or suspected neoplastic disease are eligible for participation.
- Participants will have had, or are scheduled to have clinical imaging evaluations which may include FDG PET CT, or CT, or MRI within 4 weeks of entry.
- No limit on age or gender.
- Female participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.
- Informed consent signed by participant, parent, or guardian according to the guidelines of the institutional review board.
- All participants under the care of St. Jude physicians with known or suspected neoplastic disease are eligible for participation.
- No limit on age or gender
- Female participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.
- Informed consent signed by participant, parent, or guardian according to the guidelines of the institutional review board.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Jude Children's Research Hospital Coordinator of this site? Confirm its status | Memphis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.